Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors

[img]
Preview
PDF (accepted manuscript (final draft)) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
9MB

Item Type:Article
Title:In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors
Creators Name:Richter, M. and Saydaminova, K. and Yumul, R. and Krishnan, R. and Liu, J. and Nagy, E.E. and Singh, M. and Izsvak, Z. and Cattaneo, R. and Uckert, W. and Palmer, D. and Ng, P. and Haworth, K.G. and Kiem, H.P. and Ehrhardt, A. and Papayannopoulou, T. and Lieber, A.
Abstract:Current protocols for hematopoietic stem/progenitor cell (HSPC) gene therapy, involving the transplantation of ex vivo genetically modified HSPCs are complex and not without risk for the patient. We developed a new approach for in vivo HSPC transduction that does not require myeloablation and transplantation. It involves subcutaneous injections of granulocyte-colony-stimulating factor/AMD3100 to mobilize HSPCs from the bone marrow (BM) into the peripheral blood stream and the IV injection of an integrating, helper-dependent adenovirus (HD-Ad5/35++) vector system. These vectors target CD46, a receptor that is uniformly expressed on HSPCs. We demonstrated in human CD46 transgenic mice and immunodeficient mice with engrafted human CD34+ cells that HSPCs transduced in the periphery home back to the BM where they stably express the transgene. In hCD46 transgenic mice, we showed that our in vivo HSPC transduction approach allows for the stable transduction of primitive HSPCs. Twenty weeks after in vivo transduction, green fluorescent protein (GFP) marking in BM HSPCs (Lin-Sca1+Kit- cells) in most of the mice was in the range of 5% to 10%. The percentage of GFP-expressing primitive HSPCs capable of forming multilineage progenitor colonies (colony-forming units [CFUs]) increased from 4% of all CFUs at week 4 to 16% at week 12, indicating transduction and expansion of long-term surviving HSPCs. Our approach was well tolerated, did not result in significant transduction of nonhematopoietic tissues, and was not associated with genotoxicty. The ability to stably genetically modify HSPCs without the need of myeloablative conditioning is relevant for a broader clinical application of gene therapy.
Keywords:Adenoviridae, CD46 Antigens, Genetic Therapy, Genetic Transduction, Genetic Vectors, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells, Heterografts, Intravenous Injections, Animals, Mice
Source:Blood
ISSN:0006-4971
Publisher:American Society of Hematology (U.S.A.)
Volume:128
Number:18
Page Range:2206-2217
Date:3 November 2016
Official Publication:https://doi.org/10.1182/blood-2016-04-711580
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library